Fady Gh Haddad (Fady G Haddad, Fadi G Haddad, Fady Haddad, Fadi Haddad)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 63

Top Topics

Newly Diagnosed

Tyrosine Kinase

Stem Cell Transplantation

Chronic Myeloid Leukemia

Top Venues

American journal of hematology

Future oncology (London, England)

Blood cancer journal

This page only lists publications with an associated author ORCID identifier.

Publications

Hagop M Kantarjian, Helen T Chifotides, Fady Gh Haddad, Nicholas James Short, Sanam Loghavi, Elias J Jabbour
Ponatinib-review of historical development, current status, and future research. American journal of hematology 99 (8) (2024)
Hagop M Kantarjian, Helen T Chifotides, Fady Gh Haddad, Nicholas James Short, Sanam Loghavi, Elias J Jabbour
Ponatinib-review of historical development, current status, and future research. American journal of hematology 99 (8) (2024)
Fady Gh Haddad, Koiji Sasaki, Ghayas C Issa, Elias J Jabbour, Hagop M Kantarjian
The presence of additional cytogenetic abnormalities (ACAs) or Philadelphia chromosome variants do not adversely affect the achievement of treatment-free remission in chronic myeloid leukemia. American journal of hematology 99 (6) (2024)
Fady Gh Haddad, Koiji Sasaki, Ghayas C Issa, Elias J Jabbour, Hagop M Kantarjian
The presence of additional cytogenetic abnormalities (ACAs) or Philadelphia chromosome variants do not adversely affect the achievement of treatment-free remission in chronic myeloid leukemia. American journal of hematology 99 (6) (2024)
Fady Gh Haddad, Koiji Sasaki, Jayastu Senapati, Lianchun Xiao, Grace S Hwang, Tareq Abuasab, Sangeetha Venugopal, Daniel Rivera, Alexandre Bazinet, Rodrick Babakhanlou, Kunhwa Kim, Faustine Ong, Sai Desikan, Naveen Pemmaraju, Sanam Loghavi, Gautam Borthakur, Courtney DiNardo, Hussein A Abbas, Nicholas James Short, Naval G Daver, Elias J Jabbour, Guillermo Garcia Manero, Farhad Ravandi, Hagop M Kantarjian, Tapan Mahendra Kadia
Outcomes of Patients With Newly Diagnosed AML and Hyperleukocytosis. JCO oncology practice (2024)
Hagop M Kantarjian, Nicholas James Short, Fady Gh Haddad, Nitin Jain, Xuelin Huang, Guillermo Montalban-Bravo, Rashmi Kanagal-Shamana, Tapan Mahendra Kadia, Naval G Daver, Kelly Sharon Chien, Yesid Alvarado, Guillermo Garcia Manero, Ghayas C Issa, Rebecca Garris, Cedric Nasnas, Lewis Fady Nasr, Farhad Ravandi, Elias J Jabbour
Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALL. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Jayastu Senapati, Elias J Jabbour, Nicholas James Short, Nitin Jain, Fady Gh Haddad, Tharakeswara Bathala, Iuliia Kovalenko, Aram Bidikian, Farhad Ravandi, Issa Khouri, Tapan Mahendra Kadia, Rebecca Garris, Guillermo Montalban Bravo, Kelly Chien, Elizabeth Shpall, Partow Kebriaei, Hagop M Kantarjian
Liver elastography for risk-assessment of liver toxicity and risk factors for Sinusoidal obstruction syndrome in patients with acute lymphoblastic leukemia receiving inotuzumab ozogamicin. Blood cancer journal 14 (1) (2024)
Jayastu Senapati, Hagop M Kantarjian, Alexandre Bazinet, Patrick K Reville, Nicholas James Short, Naval G Daver, Gautam Borthakur, Alex Bataller, Elias J Jabbour, Courtney D D DiNardo, Fady Gh Haddad, Koiji Sasaki, Uday R Popat, Betül Oran, Amin M Alousi, Sanam Loghavi, Elizabeth Shpall, Guillermo Garcia Manero, Farhad Ravandi, Tapan Mahendra Kadia
Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation. Cancer (2024)
Nicholas James Short, Elias J Jabbour, Lewis Fady Nasr, Nitin Jain, Fady Gh Haddad, Ghayas C Issa, Koiji Sasaki, Jayastu Senapati, Partow Kebriaei, Rebecca Garris, Marina Y Konopleva, Farhad Ravandi, Hagop M Kantarjian
Characteristics and outcomes of patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after failure of a frontline ponatinib-containing therapy. American journal of hematology 99 (7) (2024)
Hagop M Kantarjian, Helen T Chifotides, Fady Gh Haddad, Nicholas James Short, Sanam Loghavi, Elias J Jabbour
Ponatinib-review of historical development, current status, and future research. American journal of hematology 99 (8) (2024)
Nicholas James Short, Elias J Jabbour, Lewis Fady Nasr, Nitin Jain, Fady Gh Haddad, Ghayas C Issa, Koiji Sasaki, Jayastu Senapati, Partow Kebriaei, Rebecca Garris, Marina Y Konopleva, Farhad Ravandi, Hagop M Kantarjian
Characteristics and outcomes of patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after failure of a frontline ponatinib-containing therapy. American journal of hematology (2024)
Fady Gh Haddad, Koiji Sasaki, Ghayas C Issa, Elias J Jabbour, Hagop M Kantarjian
The presence of additional cytogenetic abnormalities (ACAs) or Philadelphia chromosome variants do not adversely affect the achievement of treatment-free remission in chronic myeloid leukemia. American journal of hematology (2024)
Jayastu Senapati, Elias J Jabbour, Nicholas James Short, Nitin Jain, Fady Gh Haddad, Tharakeswara Bathala, Iuliia Kovalenko, Aram Bidikian, Farhad Ravandi, Issa Khouri, Tapan Mahendra Kadia, Rebecca Garris, Guillermo Montalban Bravo, Kelly Chien, Elizabeth Shpall, Partow Kebriaei, Hagop M Kantarjian
Liver elastography for risk-assessment of liver toxicity and risk factors for Sinusoidal obstruction syndrome in patients with acute lymphoblastic leukemia receiving inotuzumab ozogamicin. Blood cancer journal 14 (1) (2024)
Fady Gh Haddad, Koiji Sasaki, Lewis Fady Nasr, Nicholas James Short, Tapan Mahendra Kadia, Sara Dellasala, Jorge Cortes, Franck Emmanuel Nicolini, Ghayas C Issa, Elias J Jabbour, Hagop M Kantarjian
Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase. Cancer 130 (19) (2024)
Wei-Ying Jen, Elias J Jabbour, Nicholas James Short, Ghayas C Issa, Fady Gh Haddad, Nitin Jain, Naveen Pemmaraju, Naval G Daver, Lucia Masarova, Gautam Borthakur, Kelly Sharon Chien, Rebecca Garris, Hagop M Kantarjian
A phase 2 trial of mini-hyper-CVD, blinatumomab, and ponatinib in Philadelphia positive acute lymphoblastic leukemia. American journal of hematology (2024)
Hagop M Kantarjian, Helen T Chifotides, Fady Gh Haddad, Nicholas James Short, Sanam Loghavi, Elias J Jabbour
Ponatinib-review of historical development, current status, and future research. American journal of hematology (2024)
Hagop M Kantarjian, Helen T Chifotides, Fady Gh Haddad, Nicholas James Short, Sanam Loghavi, Elias J Jabbour
Ponatinib-review of historical development, current status, and future research. American journal of hematology 99 (8) (2024)
Nicholas James Short, Elias J Jabbour, Lewis Fady Nasr, Nitin Jain, Fady Gh Haddad, Ghayas C Issa, Koiji Sasaki, Jayastu Senapati, Partow Kebriaei, Rebecca Garris, Marina Y Konopleva, Farhad Ravandi, Hagop M Kantarjian
Characteristics and outcomes of patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after failure of a frontline ponatinib-containing therapy. American journal of hematology 99 (7) (2024)
Elias J Jabbour, Fady Gh Haddad, Koiji Sasaki, Bing Z Carter, Yesid Alvarado, Cedric Nasnas, Lewis Fady Nasr, Lucia Masarova, Naval G Daver, Naveen Pemmaraju, Nicholas James Short, Jeffrey Skinner, Tapan Mahendra Kadia, Gautam Borthakur, Guillermo Garcia Manero, Farhad Ravandi, Ghayas C Issa, Michael Andreeff, Hagop M Kantarjian
Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia. Cancer (2024)
Fady Gh Haddad, Koiji Sasaki, Lewis Fady Nasr, Nicholas James Short, Tapan Mahendra Kadia, Sara Dellasala, Jorge Cortes, Franck Emmanuel Nicolini, Ghayas C Issa, Elias J Jabbour, Hagop M Kantarjian
Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase. Cancer (2024)
Jayastu Senapati, Elias J Jabbour, Nicholas James Short, Nitin Jain, Fady Gh Haddad, Tharakeswara Bathala, Iuliia Kovalenko, Aram Bidikian, Farhad Ravandi, Issa Khouri, Tapan Mahendra Kadia, Rebecca Garris, Guillermo Montalban Bravo, Kelly Chien, Elizabeth Shpall, Partow Kebriaei, Hagop M Kantarjian
Liver elastography for risk-assessment of liver toxicity and risk factors for Sinusoidal obstruction syndrome in patients with acute lymphoblastic leukemia receiving inotuzumab ozogamicin. Blood cancer journal 14 (1) (2024)
Elias J Jabbour, Fady Gh Haddad, Koiji Sasaki, Bing Z Carter, Yesid Alvarado, Cedric Nasnas, Lewis Fady Nasr, Lucia Masarova, Naval G Daver, Naveen Pemmaraju, Nicholas James Short, Jeffrey Skinner, Tapan Mahendra Kadia, Gautam Borthakur, Guillermo Garcia Manero, Farhad Ravandi, Ghayas C Issa, Michael Andreeff, Hagop M Kantarjian
Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia. Cancer 130 (15) (2024)
Jayastu Senapati, Hagop M Kantarjian, Alexandre Bazinet, Patrick K Reville, Nicholas James Short, Naval G Daver, Gautam Borthakur, Alex Bataller, Elias J Jabbour, Courtney D D DiNardo, Fady Gh Haddad, Koiji Sasaki, Uday R Popat, Betül Oran, Amin M Alousi, Sanam Loghavi, Elizabeth Shpall, Guillermo Garcia Manero, Farhad Ravandi, Tapan Mahendra Kadia
Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation. Cancer 130 (19) (2024)
Hagop M Kantarjian, Helen T Chifotides, Fady Gh Haddad, Nicholas James Short, Sanam Loghavi, Elias J Jabbour
Ponatinib-review of historical development, current status, and future research. American journal of hematology 99 (8) (2024)
Koiji Sasaki, Fady Gh Haddad, Nicholas James Short, Nitin Jain, Ghayas Issa, Elias J Jabbour, Hagop M Kantarjian
Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy-The Surveillance, Epidemiology, and End Results database, 2000-2019. Cancer (2023)
Fady Gh Haddad, Nicholas James Short
Treatment discontinuation in chronic myeloid leukemia: When, how, and why? American journal of hematology (2023)
Elias J Jabbour, Koiji Sasaki, Fady Gh Haddad, Ghayas C Issa, Guillermo Garcia Manero, Tapan Mahendra Kadia, Nitin Jain, Musa Ylimaz, Courtney D D DiNardo, Keyur Patel, Rashmi Kanagal-Shamana, Richard Champlin, Issa F Khouri, Sara Dellasala, Sherry A Pierce, Hagop M Kantarjian
The Outcomes of Patients with Chronic Myeloid Leukemia Treated with Third-line BCR::ABL1 Tyrosine Kinase Inhibitors. American journal of hematology (2023)
Hagop M Kantarjian, Nicholas James Short, Nitin Jain, Koji Sasaki, Xuelin Huang, Fady Gh Haddad, Issa F Khouri, Courtney D D DiNardo, Naveen Pemmaraju, William Wierda, Guillermo Garcia Manero, Partow Kebriaei, Rebecca Garris, Sanam Loghavi, Jeffrey Jorgensen, Monica Kwari, Susan O'Brien, Farhad Ravandi, Elias J Jabbour
Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results. American journal of hematology 98 (3) (2023)
Elias J Jabbour, Koiji Sasaki, Fady Gh Haddad, Ghayas C Issa, Guillermo Garcia Manero, Tapan Mahendra Kadia, Nitin Jain, Musa Ylimaz, Courtney D D DiNardo, Keyur P Patel, Rashmi Kanagal-Shamana, Richard Champlin, Issa F Khouri, Sara Dellasala, Sherry A Pierce, Hagop M Kantarjian
The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors. American journal of hematology 98 (4) (2023)
Elias J Jabbour, Koiji Sasaki, Fady Gh Haddad, Ghayas C Issa, Guillermo Garcia Manero, Tapan Mahendra Kadia, Nitin Jain, Musa Ylimaz, Courtney D D DiNardo, Keyur P Patel, Rashmi Kanagal-Shamana, Richard Champlin, Issa F Khouri, Sara Dellasala, Sherry A Pierce, Hagop M Kantarjian
The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors. American journal of hematology 98 (4) (2023)
Hagop M Kantarjian, Nicholas James Short, Nitin Jain, Koji Sasaki, Xuelin Huang, Fady Gh Haddad, Issa F Khouri, Courtney D D DiNardo, Naveen Pemmaraju, William Wierda, Guillermo Garcia Manero, Partow Kebriaei, Rebecca Garris, Sanam Loghavi, Jeffrey Jorgensen, Monica Kwari, Susan O'Brien, Farhad Ravandi, Elias J Jabbour
Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results. American journal of hematology 98 (3) (2023)
Fady Gh Haddad, Hampig Raphael Kourie, Khalil Saleh
Moving away from chemotherapy in newly diagnosed Philadelphia chromosome-positive B-cell acute lymphoblastic leukaemia. British journal of haematology (2023)
Nicholas James Short, Elias J Jabbour, Walid Macaron, Farhad Ravandi, Nitin Jain, Rashmi Kanagal-Shamana, Keyur P Patel, Sanam Loghavi, Fady Gh Haddad, Musa Ylimaz, Ghayas C Issa, Partow Kebriaei, Steven M Kornblau, Sarah Pelletier, Wilmer Flores, Jairo Matthews, Rebecca Garris, Hagop M Kantarjian
Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1. American journal of hematology (2023)
Fady Gh Haddad, Koiji Sasaki, Aram Bidikian, Ghayas C Issa, Tapan Mahendra Kadia, Nitin Jain, Yesid Alvarado, Nicholas James Short, Naveen Pemmaraju, Sanam Loghavi, Keyur P Patel, Rashmi Kanagal-Shamana, Musa Ylimaz, Lucia Masarova, Elias J Jabbour, Hagop M Kantarjian
Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era. American journal of hematology (2023)
Hagop M Kantarjian, Nicholas James Short, Nitin Jain, Koji Sasaki, Xuelin Huang, Fady Gh Haddad, Issa F Khouri, Courtney D D DiNardo, Naveen Pemmaraju, William Wierda, Guillermo Garcia Manero, Partow Kebriaei, Rebecca Garris, Sanam Loghavi, Jeffrey Jorgensen, Monica Kwari, Susan O'Brien, Farhad Ravandi, Elias J Jabbour
Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results. American journal of hematology (2023)
Elias J Jabbour, Koiji Sasaki, Fady Gh Haddad, Ghayas C Issa, Guillermo Garcia Manero, Tapan Mahendra Kadia, Nitin Jain, Musa Ylimaz, Courtney D D DiNardo, Keyur P Patel, Rashmi Kanagal-Shamana, Richard Champlin, Issa F Khouri, Sara Dellasala, Sherry A Pierce, Hagop M Kantarjian
The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors. American journal of hematology (2023)
Fady Gh Haddad, Aram Bidikian, Ghayas C Issa
Reply to "Impact of obesity surgery on tyrosine kinase inhibitor responses and survival outcomes in patients with chronic myeloid leukemia: Further data are still warranted!" Cancer (2023)
Elias J Jabbour, Koiji Sasaki, Fady Gh Haddad, Ghayas C Issa, Guillermo Garcia Manero, Tapan Mahendra Kadia, Nitin Jain, Musa Ylimaz, Courtney D D DiNardo, Keyur P Patel, Rashmi Kanagal-Shamana, Richard Champlin, Issa F Khouri, Sara Dellasala, Sherry A Pierce, Hagop M Kantarjian
The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors. American journal of hematology 98 (4) (2023)
Hagop M Kantarjian, Nicholas James Short, Nitin Jain, Koji Sasaki, Xuelin Huang, Fady Gh Haddad, Issa F Khouri, Courtney D D DiNardo, Naveen Pemmaraju, William Wierda, Guillermo Garcia Manero, Partow Kebriaei, Rebecca Garris, Sanam Loghavi, Jeffrey Jorgensen, Monica Kwari, Susan O'Brien, Farhad Ravandi, Elias J Jabbour
Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results. American journal of hematology 98 (3) (2023)
Hagop M Kantarjian, Nicholas James Short, Nitin Jain, Koji Sasaki, Xuelin Huang, Fady Gh Haddad, Issa F Khouri, Courtney D D DiNardo, Naveen Pemmaraju, William Wierda, Guillermo Garcia Manero, Partow Kebriaei, Rebecca Garris, Sanam Loghavi, Jeffrey Jorgensen, Monica Kwari, Susan O'Brien, Farhad Ravandi, Elias J Jabbour
Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results. American journal of hematology 98 (3) (2023)
Jayastu Senapati, Tareq Abuasab, Fady Gh Haddad, Farhad Ravandi, Tapan Mahendra Kadia, Courtney D D DiNardo, Naval G Daver, Naveen Pemmaraju, Yesid Alvarado, Mark A Brandt, Hagop M Kantarjian, Gautam Borthakur
Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G-CSF based regimens. American journal of hematology 98 (3) (2022)
Jayastu Senapati, Tareq Abuasab, Fady Gh Haddad, Farhad Ravandi, Tapan Mahendra Kadia, Courtney D D DiNardo, Naval G Daver, Naveen Pemmaraju, Yesid Alvarado, Mark A Brandt, Hagop M Kantarjian, Gautam Borthakur
Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G-CSF based regimens. American journal of hematology (2022)
Elias J Jabbour, Koiji Sasaki, Fady Gh Haddad, Ghayas C Issa, Jeffrey Skinner, Sara Dellasala, Musa Ylimaz, Alessandra Ferrajoli, Prithviraj Bose, Philip Thompson, Yesid Alvarado, Nitin Jain, Guillermo Garcia Manero, Koichi Takahashi, Gautam Borthakur, Naveen Pemmaraju, Sherry Pierce, Hagop M Kantarjian
Low-dose dasatinib 50 mg/day versus standard-dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis. American journal of hematology 97 (11) (2022)
Jayastu Senapati, Tareq Abuasab, Fady Gh Haddad, Farhad Ravandi, Tapan Mahendra Kadia, Courtney D D DiNardo, Naval G Daver, Naveen Pemmaraju, Yesid Alvarado, Mark A Brandt, Hagop M Kantarjian, Gautam Borthakur
Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G-CSF based regimens. American journal of hematology 98 (3) (2022)
Curtis A Lachowiez, Patrick K Reville, Hagop M Kantarjian, Elias J Jabbour, Gautam Borthakur, Naval G Daver, Ghayas C Issa, Ken Furudate, Tomoyuki Tanaka, Sherry Pierce, Guillin Tang, Keyur P Patel, Jeffrey Medeiros, Hussein A Abbas, Fady Gh Haddad, Daniel Hammond, Nicholas James Short, Abhishek Maiti, Musa Ylimaz, Koiji Sasaki, Koichi Takahashi, Naveen Pemmaraju, Marina Y Konopleva, Guillermo Garcia Manero, Farhad Ravandi, Tapan Mahendra Kadia, Sanam Loghavi, Courtney D D DiNardo
Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment. American journal of hematology 97 (11) (2022)
Jayastu Senapati, Tareq Abuasab, Fady Gh Haddad, Farhad Ravandi, Tapan Mahendra Kadia, Courtney D D DiNardo, Naval G Daver, Naveen Pemmaraju, Yesid Alvarado, Mark A Brandt, Hagop M Kantarjian, Gautam Borthakur
Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G-CSF based regimens. American journal of hematology 98 (3) (2022)
Jayastu Senapati, Tareq Abuasab, Fady Gh Haddad, Farhad Ravandi, Tapan Mahendra Kadia, Courtney D D DiNardo, Naval G Daver, Naveen Pemmaraju, Yesid Alvarado, Mark A Brandt, Hagop M Kantarjian, Gautam Borthakur
Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G-CSF based regimens. American journal of hematology 98 (3) (2022)
Fady Gh Haddad, Koiji Sasaki, Ghayas C Issa, Guillermo Garcia Manero, Farhad Ravandi, Tapan Mahendra Kadia, Jorge E Cortes, Marina Y Konopleva, Naveen Pemmaraju, Yesid Alvarado, Musa Ylimaz, Gautam Borthakur, Courtney D D DiNardo, Nitin Jain, Naval G Daver, Nicholas James Short, Elias J Jabbour, Hagop Kantarjian
Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. American journal of hematology 97 (7) (2022)
Gaëlle Haddad, Marie Christelle Saadé, Roland Eid, Fady Gh Haddad, Hampig Raphael Kourie
PARP inhibitors: a tsunami of indications in different malignancies. Pharmacogenomics 21 (3) (2021)
Fady El Karak, Elsa Rawadi, Joud Sawan, Fady Gh Haddad
The impact of disasters on cancer care in Lebanon. Future oncology (London, England) 17 (6) (2021)
Lynn Bitar, Joseph Zouein, Fady Gh Haddad, Roland Eid, Hampig R Kourie
HER2 in metastatic colorectal cancer: a new to target to remember. Biomarkers in medicine 15 (2) (2021)
Joseph Zouein, Fady Gh Haddad, Roland Eid, Hampig Raphaël Kourie
The combination of immune checkpoint inhibitors and chemotherapy in advanced non-small-cell lung cancer: the rational choice. Immunotherapy (2021)
Fady Gh Haddad, Elias Karam, Elissar Moujaess, Hampig Raphael Kourie
Poly-(ADP-ribose) polymerase inhibitors: paradigm shift in the first-line treatment of newly diagnosed advanced ovarian cancer. Pharmacogenomics 21 (10) (2020)
Ronaldo Elkaddoum, Fady Gh Haddad, Roland Eid, Hampig Raphael Kourie
In reply to: incorporating teleoncology practices in the undergraduate medical curriculum. Future oncology (London, England) 17 (1) (2020)
Hampig Raphael Kourie, Roland Eid, Fady Gh Haddad, Michel Scheuer, Roland Tomb
Bioethical considerations for cancer patient care during the COVID-19 pandemic. Future oncology (London, England) 16 (34) (2020)
Hampig Raphael Kourie, Roland Eid, Fady Gh Haddad, Marwan Ghosn, Dolla Karam Sarkis
The future of cancer research after COVID-19 pandemic: recession? Future oncology (London, England) 16 (21) (2020)
Hampig Raphael Kourie, Roland Eid, Fady Gh Haddad
Agnostic biomarkers in gastrointestinal tumors: microsatellite instability and NTRK. Personalized medicine 18 (1) (2020)
Ronaldo Elkaddoum, Fady Gh Haddad, Roland Eid, Hampig Raphael Kourie
Telemedicine for cancer patients during COVID-19 pandemic: between threats and opportunities. Future oncology (London, England) 16 (18) (2020)
Fady Gh Haddad, Clarisse Kattan, Joseph Kattan
Should immune checkpoint inhibitors be contraindicated in lung cancer patients with latent tuberculosis? Immunotherapy 12 (11) (2020)
Marwan Alkassis, Fady Gh Haddad, Joseph Gharios, Roger Noun, Ghassan Chakhtoura
Quality of Life before and after Sleeve Gastrectomy in Lebanese Population. Journal of obesity 2019 (2019)
Joseph Kattan, Fady Gh Haddad, Lina Menassa-Moussa, Carole Kesrouani, Stephanie Daccache, Fady G Haddad, David Atallah
Peritoneal Tuberculosis: A Forsaken Yet Misleading Diagnosis. Case reports in oncological medicine 2019 (2019)
Elissar Moujaess, Fady Gh Haddad, Roland Eid, Hampig Raphael Kourie
The emerging use of immune checkpoint blockade in the adjuvant setting for solid tumors: a review. Immunotherapy 11 (16) (2019)
Mira Akiki, Fady Gh Haddad, Hampig Raphael Kourie, Abir Khaddage, Viviane Track Smayra
PD-L1: an unavoidable biomarker in advanced triple-negative breast cancer. Biomarkers in medicine 13 (18) (2019)